ClinicalTrials.Veeva

Menu

Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus (ATTAIN2)

Cumberland Pharmaceuticals logo

Cumberland Pharmaceuticals

Status and phase

Completed
Phase 3

Conditions

Bacterial Pneumonia

Treatments

Drug: Vancomycin
Drug: Telavancin

Study type

Interventional

Funder types

Industry

Identifiers

Details and patient eligibility

About

Study 0019 (NCT00124020) compares the safety and effectiveness of an investigational drug, telavancin, with vancomycin for the treatment of hospital-acquired pneumonia.

Enrollment

771 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Clinical signs and symptoms consistent with pneumonia acquired after at least 48 hours of continuous stay in an inpatient acute or chronic care facility or acquired within 7 days after being discharged from a hospitalization of greater than or equal to 3 days duration.

Exclusion criteria

  • Received more than 24 hours of potentially effective systemic (IV, IM or PO) antibiotic therapy for Gram-positive pneumonia immediately prior to randomization.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

771 participants in 2 patient groups

Telavancin
Experimental group
Treatment:
Drug: Telavancin
Vancomycin
Active Comparator group
Treatment:
Drug: Vancomycin

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems